Two patients (patients A and B) infected with Salmonella typhimurium failed ciprofloxacin therapy, and the posttherapy isolates had reduced susceptibilities to quinolones; 6 of 11 isolates from patient B were also cross-resistant to chemically unrelated agents. No transferable resistance, chloramphenicol-acetylating enzymes, or 13-lactamases were detected. For 13 of 14 isolates, the concentrations of ciprofloxacin that inhibited DNA synthesis by 50%o were similar to the MICs, suggesting a mutation in gyrA. Insertion of pNJR3-2 (gyrA) in the posttherapy isolate from patient A and 5 of 11 of the posttherapy isolates from patient B resulted in lower quinolone MICs, also suggesting that resistance was due to a mutation in gyrA.
The antimicrobial therapy of salmonella infections presents a therapeutic challenge to the clinician (7, 18) . Although the course of salmonella enteritis is usually selflimiting and needs no antibacterial chemotherapy, patients who are severely ill, who are immunocompromised, or who have invasive infection require immediate antibiotic treatment (7, 18) . Ampicillin, chloramphenicol, and co-trimoxazole have been the antibiotics of choice for the treatment of salmonellosis, but the increase in the number of strains that are resistant to these commonly used agents is disturbing (10) . The emergence of multiresistant strains of salmonellae has led to the evaluation of the fluoroquinolones for the treatment of salmonellosis (7) . Quinolones, such as ciprofloxacin, have potent activity in vitro against salmonellae (26) and have rapid bactericidal activity, even against multiresistant strains (18) . Epidemics of multiresistant Salmonella spp. in developing countries have been managed successfully with quinolone therapy (22, 23) .
However, the emergence of quinolone resistance in salmonellae is a matter of concern. There have been several reports of treatment failure because of the emergence of ciprofloxacin resistance in Salmonella typhimurium during therapy (6, 15) . In addition, Hof et al. (4) described the isolation of a highly quinolone-resistant S. typhimurium isolate from the stool of a patient not previously exposed to quinolone therapy. Lewin et al. (8) have also reported on nalidixic acid-resistant strains of S. typhimurium isolated in India.
The mechanisms of quinolone resistance in other members of the family Enterobacteriaceae have been characterized, and in Escherichia coli resistance essentially falls into two classes: mutations in gyrA or gyrB affecting the interaction between the target enzyme, DNA gyrase, and the quinolone or from reduced levels of quinolone accumulation into the cell. This may be due to mutations in marA or ompF that affect the expression of OmpF or possibly may be due to * Corresponding author.
unidentified mutations that affect non-porin pathways such as the lipopolysaccharide (LPS) (16) .
Little is known of the mechanisms of quinolone resistance in salmonellae. In parallel to the present study, Howard et al. (6) found substantially reduced levels of expression of OmpF in a ciprofloxacin-resistant posttherapy strain of S. typhimurium, whereas Lewin et al. (8) found no difference in the Omp profiles of four nalidixic acid-resistant S. typhimurium strains compared with those of susceptible strains.
In the present study, we sought to characterize the mechanisms of quinolone resistance in the clinical isolates of S. typhimurium obtained from two patients who failed ciprofloxacin therapy (12, 15 Preparation of OMPs, LPS, and electrophoresis. The outer membrane proteins (OMPs) of all isolates were prepared by differential centrifugation, sonication, and sarcosyl extraction as described by Piddock et al. (14) . All samples were electrophoresed on sodium dodecyl sulfate (SDS)-10% vertical polyacrylamide gels by using 20 ,ug of protein per channel. The LPSs of all isolates were prepared by boiling the bacterial membrane preparation in sample buffer (0.SM Tris-HCl [pH 6.8], SDS, glycerol, bromophenol blue, mercaptoethanol), adding 50 ,ug of proteinase K, and incubating the samples overnight at 55°C. Electrophoresis was performed on SDS-4M urea polyacrylamide gels and were stained with silver by the procedure of Tsai and Frasch (21) .
Accumulation of quinolones. The modified fluorescence method was used for measuring the accumulation of all quinolones essentially as described by Mortimer and Piddock (9) . The accumulation data were converted and expressed as nanograms of quinolone per milligram (dry weight) of cells.
Assay of DNA synthesis. The procedure for measuring the inhibition of DNA synthesis by ciprofloxacin and nalidixic acid was that usually used to measure the incorporation of
[3H]adenine into Pseudomonas aeruginosa, and was performed essentially as described by Benbrook and Miller (1) . The concentration of each drug that inhibited DNA synthesis by 50% was determined from the linear portion of the inhibition curve.
Identification of isolates with mutations in gyrA with pNJR3-2 containing wild-type E. coli gyrA. E. coli S17-1 with plasmid pNJR3-2 containing gyrA encoding a quinolonesusceptible DNA gyrase (19) was conjugated with all resistant isolates essentially as described by Piddock and Zhu (17) . After conjugation, the transconjugants were harvested into ML broth (10 g of tryptone, 5 g of yeast extract, 5 g of sodium chloride, 2 g of dipotassium hydrogen phosphate per liter) containing 2 ,ug of tetracycline per ml, and the mixture was incubated overnight at 37°C. Dilutions of the recoveryphase broth were used to inoculate ML agar selection plates containing 10, 20, and 100 ,ug of tetracycline per ml, and the plates were incubated overnight at 37°C. Replica plates were made on MacConkey agar (Unipath) and fresh ML agar with 10, 20, and 100 ,ug of tetracycline per ml, and the plates were incubated overnight at 37°C. Donor (lactose-fermenting) and salmonella transconjugate (non-lactose-fermenting) colonies could be easily distinguished on MacConkey agar. Ten transconjugate colonies were identified from the selection plates, and the susceptibility of each putative transconjugant was determined. Ten micrograms of tetracycline per milliliter was added to all media for susceptibility testing of the transconjugant to maintain the plasmid. The plasmid pLA2917, which is identical to pNJR3-2 except that it lacks the gyrA gene, was used as a control. The presence of the plasmids pNJR3-2 and pLA2917 in transconjugants was confirmed by agarose gel electrophoresis. Plasmid DNA was extracted by alkaline lysis (2) and electrophoresed in 0.7% agarose gels in TBE buffer (20) HindIll. Identical profiles were obtained for the digested DNAs from both isolates from patient A and from all isolates from patient B, although the patterns of the digested DNAs from the isolates from the two patients were different (data not shown). The serotype, phage type, plasmid profiles, and restriction digest data showed that (i) the isolates from the two patients were distinct from each other and from the National Collection of Type Cultures (NCTC) type strain (L19), (ii) the isolates from patient A could be considered isogenic, (iii) 9 of 11 isolates from patient B could be considered isogenic, and (iv) the remaining two isolates were probably derived from the pretherapy isolate L3. There was no clinical evidence of reinfection in patient B. Both isolates from patient A had a mean doubling time of 43.5 min, whereas the NCTC type strain and all isolates from patient B had mean doubling times of 20 min.
Susceptibility. The posttherapy isolate L2 from patient A was 64-fold less susceptible to ciprofloxacin than was isolate Li (Table 1) (Table 1) . However, some isolates from patient B had reduced levels of accumulation (Fig. 2) Conijugation with E. coli containing quinolone-susceptible gyrA. All isolates were conjugated with E. coli S17-1 containing pNJR3-2 and pLA2917. None of the transconjugants containing pLA2917 had increased susceptibility to quinolones (data not shown). Those isolates that contained pNJR3-2 and that had increased susceptibilities to nalidixic acid, ciprofloxacin, norfloxacin, enoxacin, and ofloxacin were presumed to possess a mutation in gyrA (Table 1) . For the transconjugants of the posttherapy isolate (L2) from patient A and six posttherapy isolates (IA, L5, Lii, L13, L14, L16) from patient B, the MICs of quinolones (but not those of chloramphenicol or cefoxitin) were reduced when pNJR3-2 was inserted ( Table 1) . Five of these six isolates were not cross-resistant to other agents. Three cross-resistant isolates (110, L15, L18) contained pNJR3-2 but had no increased susceptibility. In the two remaining isolates, L6 and L12, pNJR3-2 could not be clearly seen on agarose electrophoresis, and the susceptibilities of these two isolates were unchanged. DISCUSSION The preliminary report of the isolates described here was the first publication documenting quinolone resistance arising in salmonellae during quinolone therapy (15) . The data from the typing methods suggested that the isolates from each patient were distinct but that those from each patient were derived from the same strain. The coincidental development of ciprofloxacin resistance associated with therapeutic failure in two patients is worrying. Of most concern is the susceptibility data, because the posttherapy isolates from patient B were inhibited by concentrations of ciprofloxacin well below the recommended breakpoint concentration for this agent in the United Kingdom (1 ,ug/ml). Patient B did not have abnormal pharmacokinetics, and the correct dose of ciprofloxacin was given (25) ; therefore, the reason for the failure of therapy is presumably the decrease in the susceptibilities of the infecting organisms. The management of patient B was further compromised by the cross-resistance of some of the isolates to unrelated agents.
The biochemical data and the data obtained in the conjugation experiments suggest that the posttherapy isolate from patient A contained a mutation in gyrA. However, for the posttherapy isolates from patient B, the data suggest that several phenotypes arose during treatment. First, the data suggest that all five isolates that were resistant to quinolones alone had mutations in gyrA. However, three of these five isolates also had reduced levels of accumulation of quinolones. Second, all six isolates that were cross-resistant to other agents had reduced levels of accumulation of quinolones. pNJR3-2 was inserted in four of these six isolates, but the data suggested that only one isolate had a mutation in gyrA. pNJR3-2 could not be inserted into the remaining two isolates. Bacteria with mutations in gyrA are usually stably resistant to quinolones; however, four isolates in the present study easily reverted to susceptibility. This suggests the involvement of another gene that causes the resistance. (3, 5, 13) . In fact, the lack of OmpF or OmpC in salmonellae would seem to be misleading and unrelated to susceptibility. However, the reduced steady-state concentrations were apparently not due to altered LPS profiles, since our analysis failed to reveal differences in the LPSs from these isolates. Enhanced quinolone efflux from these isolates as a mechanism of resistance must be considered, but it has not yet been identified in other gram-negative bacteria.
Despite insertion of the probe pNJR3-2 (gyrA) and DNA synthesis data suggesting a mutation affecting the target enzyme, two isolates that contained pNJR3-2 did not appear to have mutations in gyrA. Recently, Weidemann (24) has shown that some quinolone-resistant salmonellae contain mutations in gyrB alone or in addition to those in gyrA. The concentration of quinolone required to inhibit the DNA synthesis of the remaining isolate (L15) did not correlate with the MIC, but it was similar to the concentration that inhibited the pretherapy isolate. In addition, this strain accumulated quinolones poorly and L15(pNJR3-2) had unchanged susceptibility. These data suggest that this isolate was a permeability mutant.
To confirm the data obtained in the present study, amplification of gyrA and DNA sequencing is under way. However, the primers used for amplification ofgyrA from E. coli (11) did not amplify gyrA from the salmonellae from either patient or control strains. By using mixed oligonucleotide primers, a fragment of gyrA was amplified from the NCTFC type strain and L88 (the control gyrA mutant). The precise identification of the mutation(s) in gyrA and/or gyrB will greatly enhance the clinical relevance of the present study, because it may be that multiple mutations are responsible, which may be rare.
It was thought that ciprofloxacin-resistant clinical isolates of salmonellae failing fluoroquinolone therapy would occur very rarely, first, because of the high concentrations achievable at various body sites and, second, because this species is extremely susceptible to fluoroquinolones. However, until epidemiological information is available, clinicians should be aware that quinolone therapy may not be the most appropriate therapy for multiply resistant salmonellae.
